Search Medical Condition
Please enter condition
Please choose location from dropdown
 

Richmond, Australia Clinical Trials

A listing of Richmond, Australia clinical trials actively recruiting patients volunteers.

RESULTS

Found (678) clinical trials

Durvalumab and Tremelimumab Platinum-Based Chemotherapy in Patients With Metastatic Squamous or Non-Squamous NSCLC

Combinations of durvalumab and tremelimumab have also been studied. While the combination has been studied in over 200 people, it is not clear if it can offer better results when it is combined with chemotherapy. Recently, immunotherapies that target the PD-1/PD-L1 axis have shown promise in treating patients with non-small ...

Phase

0.0 miles

Learn More »

A Study of ALKS 5461 for Treatment Refractory Major Depressive Disorder (MDD)

This study will evaluate the efficacy, safety, and tolerability of adjunctive ALKS 5461 in adults who have treatment refractory MDD.

Phase

0.0 miles

Learn More »

NLA101 in Adults Receiving High Dose Chemotherapy for AML

Phase 2 open-label, multi-center, randomized, controlled, dose-finding study of safety and efficacy of NLA101 to reduce the rate of infections associated with chemotherapy induced neutropenia (CIN) in adult subjects with AML. Eligible subjects with untreated de novo or secondary AML and per local institutional standards planned to receive at least ...

Phase

0.0 miles

Learn More »

Rapid Point-of-care Testing for Hepatitis C in Community Clinics (RAPID-EC)

The introduction of direct-acting antiviral (DAA) therapies has meant the elimination of hepatitis C (HCV) as a public health issue in Australia is a very real possibility. The challenge that remains is to ensure that all people living with HCV can access testing to become aware of their status, and ...

Phase N/A

0.0 miles

Learn More »

The EVICEL Neurosurgery Phase III Study

The objective of this study is to evaluate the safety and efficacy of EVICEL® Fibrin Sealant (Human) for use as an adjunct to sutured dural repair in cranial surgery.

Phase

0.0 miles

Learn More »

Docetaxel + Plinabulin Compared to Docetaxel + Placebo in Patients With Advanced NSCLC

Lung cancer is the leading cause of cancer-related mortality worldwide. A report published by the WHO in February 2014, estimated there were 1.83 million new cases and 1.59 million deaths worldwide in 2012. The American Lung Association reports 399,431 Americans living with lung cancer, with an estimated 221,200 new cases ...

Phase

0.0 miles

Learn More »

A Dose-escalation Study of ARX788 IV Administered in Subjects With Advanced Cancers With HER2 Expression

This is a 2-part, Phase 1 FIH study with Phase 1a designed to determine the maximum tolerated dose (MTD)/recommended Phase 2 dose (RP2D) in subjects with metastatic cancers with a human epidermal growth factor receptor 2 (HER2) test result that is in situ hybridization (ISH) positive (+) or immunohistochemistry (IHC) ...

Phase

0.0 miles

Learn More »

The DIAMOND for the Treatment of Type 2 Diabetes

Study to evaluate the efficacy of gastric stimulation (GCM) using the DIAMOND System in the improvement of glycemic control measured by changes in HbA1c. Relationship between blood TG level and the GCM efficacy will be evaluated.

Phase N/A

0.0 miles

Learn More »

Double Blind Placebo Controlled Controlled Study of Adjuvant MEDI4736 In Completely Resected NSCLC

The purpose of this study is to find out whether it is better to receive a new drug, MEDI4736, or better to receive no further treatment after surgery (and possibly chemotherapy) for lung cancer.

Phase

0.0 miles

Learn More »

Study to Evaluate Efficacy and Safety of PF-04965842 With or Without Topical Medications in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis

B7451015 is a Phase 3 study to evaluate PF-04965842 with or without Topical Medications in patients aged 12 years and older with a minimum body weight of 40 kg who have moderate to severe atopic dermatitis and have completed a qualifying Phase 3 study. The efficacy and safety of two ...

Phase

0.0 miles

Learn More »